Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at six months Semaglutide 2.4 mg was also associated with significantly greater reductions...
Covered in this story
Call it yourself
No calls on $ASB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Associated Bancorp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.